← Ascendis Pharma A/S ASND
Market Price
$248.68
Market Cap
$15.22B
P/E Ratio
N/A
Revenue (FY 2025)
↑98.0% YoY
$720.13M
3-Yr CAGR: 141.4%
Net Income
↑39.7% YoY
-$228.03M
Net Margin: -31.7%
Free Cash Flow
↓-135.9% YoY
-$1.81M
FCF Yield: -0.01%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity
Efficiency
N/A
ROA: -17.5%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (ASND)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2017: Revenue YoY (-66.8%) is identical to Gross Profit YoY (-66.8%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
- FY 2018: Revenue YoY (+591.6%) is identical to Gross Profit YoY (+591.6%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
- FY 2019: Revenue YoY (+26.4%) is identical to Gross Profit YoY (+26.4%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $4.6M | — | $3.6M | $-68.7M | — | — | — | $-0.6M | — | — |
| FY 2017 | $1.5M | -66.8% | $1.2M | $-124.4M | -81.0% | — | — | $-0.2M | $-1.1M | — |
| FY 2018 | $10.6M | +591.6% | $8.2M | $-130.5M | -4.9% | — | — | $-0.3M | $-3.0M | -172.4% |
| FY 2019 | $13.4M | +26.4% | $10.4M | $-218.2M | -67.3% | — | — | $0.3M | $-4.9M | -63.8% |
| FY 2020 | $7.0M | -48.0% | $5.0M | $-419.0M | -92.0% | — | — | $-1.1M | $-21.0M | -329.4% |
| FY 2021 | $7.8M | +11.9% | $4.3M | $-383.6M | +8.4% | — | — | $-0.2M | $-23.9M | -13.8% |
| FY 2022 | $51.2M | +557.9% | $20.5M | $-583.2M | -52.0% | — | — | $0.0M | $-5.0M | +79.2% |
| FY 2023 | $266.7M | +421.2% | $222.3M | $-481.4M | +17.4% | — | — | $4.5M | $2.1M | +141.9% |
| FY 2024 | $363.6M | +36.3% | $298.1M | $-378.1M | +21.5% | — | — | $5.5M | $5.0M | +142.7% |
| FY 2025 | $720.1M | +98.0% | $625.2M | $-228.0M | +39.7% | — | — | $6.7M | $-1.8M | -135.9% |
Valuation
Market Price
$248.68
Market Cap
$15.22B
Enterprise Value
N/A
P/E Ratio
N/A
P/B Ratio
N/A
FCF Yield
-0.01%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
86.82%
Operating Margin
-18.92%
Net Margin
-31.67%
Return on Equity (ROE)
N/A
Return on Assets (ROA)
-17.51%
Asset Turnover
0.55x
Revenue 3-Yr CAGR
141.43%
Financial Health & Liquidity
Current Ratio
N/A
Cash Ratio
N/A
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
N/A
Total Debt
N/A
Book Value / Share
N/A
Cash Flow Efficiency
Operating Cash Flow
$6.68M
Capital Expenditures (CapEx)
$8.48M
Free Cash Flow
-$1.81M
OCF / Revenue
0.93%
FCF / Revenue
-0.25%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
N/A
EPS (Basic)
N/A
Dividends / Share
N/A
Book Value / Share
N/A
EPS YoY Growth
N/A
Balance Sheet (FY 2025)
Total Assets
$1.30B
Total Liabilities
$1.47B
Stockholders' Equity
N/A
Current Assets
$1.78M
Current Liabilities
N/A